Robust Immune Responses Are Observed after One Dose of BNT162b2 mRNA Vaccine Dose in SARS-CoV-2 Experienced Individuals

Scientists evaluated longitudinal immune responses to two-dose BNT162b2 mRNA vaccination in 15 adults who had experienced COVID-19, compared to 21 adults who did not have prior COVID-19.